AIML.CN AI/ML Innovations Inc. (CNQ) C$0.04 16 Mar 2026: Liquidity and risk

We open market hours on 16 Mar 2026 with AIML.CN stock trading at C$0.04 on the CNQ in Canada, showing steady intraday range C$0.04–C$0.045 and volume of 542,000.00 shares. The company, AI/ML Innovations Inc., operates AI and ML health software and wearable tech and reports negative earnings with EPS -0.03 and PE -1.33. In this update we focus on liquidity, valuation, recent technicals and a model-based forecast to help frame short-term risk and opportunity for AI sector investors using Meyka AI-powered market analysis.

AIML.CN stock snapshot

AIML.CN stock trades at C$0.04 with a market cap near C$6,730,560.00 and shares outstanding 168,264,000.00. Day range is C$0.04–C$0.045, year high C$0.12 and year low C$0.03, and average volume is 433,559.00 versus today’s 542,000.00, signalling higher-than-normal activity.

Financials and valuation: AIML.CN analysis

The company posts negative profitability with EPS -0.03 and PE at -1.33, and a price-to-sales ratio around 45.00, reflecting tiny revenue per share. Balance metrics show a current ratio 2.09 and modest debt-to-equity 0.11, but operating cash flow per share is negative at -0.03, underlining cash burn.

Technical view and liquidity

Technically AIML.CN shows muted momentum: RSI 53.32 and ADX 20.17, with Bollinger bands tight at C$0.03–C$0.04, so short-term movement is range-bound. Relative volume of 1.25 and on‑exchange liquidity remain limited, so trade size can move price materially on CNQ.

Meyka grade and forecast

Meyka AI rates AIML.CN with a score out of 100: 62.26 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of C$0.02, implying -50.00% vs the current C$0.04; forecasts are model-based projections and not guarantees.

Risks and opportunities for AI/ML Innovations

Risk drivers include low revenue per share, negative margins, and thin liquidity that amplify downside in downturns. Opportunity lies in the company’s patent-pending personal health monitoring tech within the healthcare AI sector, which could drive re-rating if commercial traction appears.

Trading strategy and price targets

For active traders we recommend strict position sizing given volatility and low float; use stop-losses under the C$0.03 level. Reasonable scenario targets: conservative C$0.02, baseline C$0.04, upside recovery C$0.08 with a stretch to the year high C$0.12 if commercial wins materialize.

Final Thoughts

Key takeaways: AIML.CN stock trades at C$0.04 on CNQ with small market cap and thin liquidity that creates elevated trading risk. Financials show negative EPS -0.03 and a high price-to-sales ratio 45.00, indicating valuation is tied to future execution rather than current revenue. Meyka AI rates the stock 62.26 (B, HOLD) and its model projects a yearly price near C$0.02, implying -50.00% downside versus today’s price; this highlights downside sensitivity if product adoption stalls. We view AIML.CN as a speculative AI healthcare equity best suited to risk‑aware traders and investors who can tolerate potential deep drawdowns and monitor commercial milestones closely. For active positions keep exposure small, set strict stops, and track volume and news flow for signs of contract wins or partnerships that could re-rate the stock. Meyka AI provides this AI‑powered market analysis to clarify model-based scenarios; forecasts are not guarantees and do not replace independent research.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.